Business
Tango Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Highlights
– Dose expansion ongoing in TNG908 and TNG462 phase 1/2 clinical trials; comprehensive clinical data update for the PRMT5 program expected in 2H 2024 – –
About this update from Tango Therapeutics, Inc.
[{"type":"text","content":"\n– Dose expansion ongoing in TNG908 and TNG462 phase 1/2 clinical trials; comprehensive clinical data update for the PRMT5 program expected in 2H 2024 –\n\n\n– Patient enrollment is ongoing in TNG260 phase 1/2 clinical trial –\n\n\n– Strong cash position of $322 million as of June 30, 2024; cash runway into 2027 expected to fund clinical programs through proof-of-concept –\n\n\n BOSTON--(BUSINESS WIRE)--\nTango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, reported its financial results for the second quarter ended June 30, 2024, and provided business highlights.\n\n\n“In the second quarter, we continued to advance the dose expansion portions of the TNG908 and TNG462 phase 1/2 clinical trials. We are progressing these molecules with the intent of remaining a leader in developing PRMT5 inhibitors for multiple cancers. We look forward to sharing a comprehensive clinical data update for the PRMT5 program later this year,” said Barbara Weber, M.D., President and Chief Executive Officer of Tango Therapeutics. “In addition, we continue to advance TNG260 for cancers with STK11 loss-of-function mutations and patient enrollment is ongoing in the phase 1/2 clinical trial.”\n\n\nRecent Business Highlights\n\n\nPipeline Update\n\n\nTNG908, a blood-brain barrier penetrant, MTA-cooperative PRMT5 inhibitor\n\n\n\nEnrollment in the dose expansion portion of the TNG908 phase 1/2 clinical trial is ongoing. Expansion cohorts are being enrolled in MTAP-deleted solid tumors in glioblastoma (GBM), non-small cell lung and pancreatic cancers at 600 mg BID.\n\n\n\nMTAP deletions occur in approximately 10%-15% of all human cancers, including 40% of GBM.\n\n\n\nTNG462, a potentially best-in-class MTA-cooperative PRMT5 inhibitor\n\n\n\nThe dose expansion portion of the TNG462 phase 1/2 clinical trial is ongoing. Two doses are being evaluated (200 mg QD and 300 mg QD) in non-small cell lung and pancreatic cancer, as well as a histology-agnostic cohort enriched for cholangiocarcinoma, mesothelioma, sarcoma and bladder cancers.\n\n\n\nTNG260, a first-in-class, highly selective CoREST complex inhibitor\n\n\n\nThe TNG260 phase 1/2 clinical trial is ongoing, evaluating the safety, pharmacokinetics, pharmacodynamics and efficacy of TNG260 in com...